DGAP-News: aap: General data for bank technical implementation of ordinary capital reduction

aap Implantate AG ("aap" or the "Company") announces the general data for the bank technical implementation of the ordinary capital reduction.

Metadata

Provider:

EQS

Retrieved on:

Wednesday, October 21, 2020

Information

Tags:

Financial markets, Frankfurt, Finance, Xetra, Frankfurt Stock Exchange, Stock

⚠ generated by AI ↴

Organisation:

AAP IMPLANTATE AG

Summary

Key Points:

aap Implantate AG ("aap" or the "Company") announces the general data for the bank technical implementation of the ordinary capital reduction.
Now that the capital reduction has been entered into the commercial register on October 5, 2020, it is planned to switch trading on the Frankfurt Stock Exchange on October 29, 2020.
It is planned to book the new shares or numbers of shares in shareholders' securities accounts on November 2, 2020.
aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE).

DGAP-News: aap Implantate AG

/ Key word(s): Corporate Action/Capital Reorganisation

aap: General data for bank technical implementation of ordinary capital reduction

21.10.2020 / 16:25

The issuer is solely responsible for the content of this announcement.

aap Implantate AG ("aap" or the "Company") announces the general data for the bank technical implementation of the ordinary capital reduction. Now that the capital reduction has been entered into the commercial register on October 5, 2020, it is planned to switch trading on the Frankfurt Stock Exchange on October 29, 2020. This will entail a change in the quotation of aap shares at a ratio of 10 to 1, which will reduce the number of shares traded to 3,206,737 and should increase the share price about tenfold. It is planned to book the new shares or numbers of shares in shareholders' securities accounts on November 2, 2020. Each 10 shares with a proportionate amount of the share capital of EUR 1.00 each (ISIN DE0005066609) will then be replaced by one converted share with a proportionate amount of the share capital of EUR 1.00 (ISIN DE000A3H2101).

----------------------------------------------------------------

aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:

aap Implantate AG; Fabian Franke; Manager Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49/30/750 19 - 134; Fax: +49/30/750 19 - 290; Email: [email protected]

21.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	aap Implantate AG
	Lorenzweg 5
	12099 Berlin
	Germany
Phone:	+49 (0) 30 75 01 90
Fax:	+49 (0) 30 75 01 91 11
E-mail:	[email protected]
Internet:	www.aap.de
ISIN:	DE0005066609
WKN:	506660
Listed:	Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1142295


End of News	DGAP News Service

1142295 21.10.2020